Four products, four ongoing prices
One sentence carries the first-month rate and then the ongoing monthly price for the flex-dose injection, the oral dissolving tablet, the tirzepatide injection and the sublingual tirzepatide. That is unusually complete for a lane that sits inside a menopause-led brand.
Twenty-seven of the one hundred and fifty-eight sellers here price an oral route at all. Pricing two of them, one for each molecule, and giving each its own ongoing figure rather than an upsell inside an injection plan, is the clearer way to do it.
The pricing has one genuine oddity worth reading twice: the sublingual tirzepatide is cheaper than the tirzepatide injection, and more expensive than the semaglutide injection. Route and molecule pull in opposite directions here.
The membership question, answered twice
A band running across the priced page and the privacy policy repeats that there are no membership fees and that the consultation fee is covered. The body of the page states the consultation fee and says it is covered.
Fifty-five of the one hundred and fifty-eight sellers here state that no membership applies. Stating it on the legal pages as well as the marketing page is a stronger form of the claim than one line in a hero.
The page also explains its own price difference between the two molecules in plain words, which almost nothing here does.
Two companies, one policy page
The privacy policy names a corporation with the brand in its name in the body text and carries a copyright line naming a completely different company at the foot of the same page. Both are recorded.
The Terms name the affiliated medical practice and the fulfilling pharmacy, which puts this seller among the thirty-two of the one hundred and fifty-eight here that name a pharmacy at all.
No individual clinician is named and no service area is published.
Kina's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $199/mothe ongoing monthly price for the Flex Dose injection, published in a single sentence that also carries the other three products | September 2026source |
| Semaglutide (compounded-oral) | $279/mothe ongoing monthly price for the oral dissolving tablet, the most expensive of the four products on this page | September 2026source |
| Tirzepatide (compounded) | $249/mothe ongoing monthly price for the injection; the page explains its own price gap, saying semaglutide "is more affordable at $199/mo vs $249/mo" | September 2026source |
| Tirzepatide (compounded-oral) | $229/mothe ongoing monthly price for the sublingual tirzepatide, which is cheaper than the injection of the same drug and more expensive than the injection of the other | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Kina's current price →Good fit if
- Buyers comparing an injection against an oral of the same drug with both ongoing rates published.
- Readers who want the membership position stated on the legal pages as well as the marketing ones.
- People who want the fulfilling pharmacy and the prescribing practice named.
Look elsewhere if
- Anyone who needs to know which company they are contracting with.
- Buyers who want an individual prescriber named.
- Readers who need a service-area list.
- People who want a dose ladder rather than four flat product rates.
How this review was verified
- Read the weight page and the privacy policy on 6 September 2026, with a nonsense-path control on the host in the same run.
- Took all four ongoing prices from the sentence that carries them together, rather than from the page headline, which quotes only the first-month figure.
- Recorded both company names published on the privacy policy, from the body and the footer of the same page.
- Checked that the first-month figure equals the cheapest ongoing rate less the automatic discount the page describes, and it does.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.